Fact-checked by Grok 2 weeks ago

bioMérieux

bioMérieux is a multinational company specializing in the development and production of diagnostic solutions, particularly for detecting and managing infectious diseases. Founded in 1963 by Alain Mérieux as a of the Institut Mérieux, the company traces its roots to 1897 when Marcel Mérieux, a student of , established the Institut Mérieux in to develop the first anti-tetanus serum and advance vaccinology and . Today, bioMérieux remains family-owned under the Institut Mérieux holding and has grown into a global leader in diagnostics, employing approximately 14,600 people worldwide. The company's core technologies encompass , immunoassays, and , enabling rapid and accurate testing for pathogens in clinical, , and applications. Key products include the BIOFIRE® panels for multiplex , such as the Respiratory 2.1 Panel for identifying respiratory pathogens, and automated systems like SPOTFIRE® for . bioMérieux's innovations have significantly contributed to responses, including during pandemics, by providing tools for early detection and monitoring. Headquartered in Marcy-l'Étoile near , , bioMérieux operates in 45 countries and distributes its products to over 160 nations, with more than 93% of sales generated outside . In the first nine months of 2025, the company reported revenues of €2,992 million, reflecting 7.3% organic growth, driven by strong performance in non-respiratory BIOFIRE® panels and industrial applications. Under its GO•28 strategic plan, bioMérieux continues to invest in , leveraging over a century of expertise in infectious disease management to pioneer diagnostics that improve patient outcomes and .

Overview

Founding and Legal Status

bioMérieux was founded in 1963 by Alain Mérieux as a from Institut Mérieux, focusing initially on diagnostics. The company's historical roots trace back to 1897, when Marcel Mérieux, a student of , established Institut Mérieux in to advance biological research and vaccine production. As a Société Anonyme, bioMérieux operates as a and has been listed on since 1997 under the BIM, with FR0013280286; it is also a component of the index. The company's headquarters are located in Marcy-l'Étoile, near , . bioMérieux maintains a family-owned heritage through its ongoing connection to Institut Mérieux. As of the end of , the company employed approximately 14,800 people worldwide.

Core Business and Mission

bioMérieux is a company specializing in diagnostics (IVD), focusing on the development and production of solutions that detect diseases and prevent to enhance outcomes. Its core mission is to pioneer, develop, and produce high-quality diagnostics aimed at improving worldwide by advancing the frontiers of . Rooted in the legacy of Louis Pasteur's contributions to , the company emphasizes innovative approaches to disease detection and microbial safety. The company's operations are divided into two primary business segments: clinical diagnostics, which target infectious diseases, oncology, and cardiovascular conditions to support care in healthcare settings, and applications, which provide microbiological testing solutions for assurance in the agri-food, pharmaceutical, and industries. In 2024, bioMérieux reported revenues of €3.98 billion, with over 93% of sales occurring outside , reflecting its extensive international footprint and reliance on global markets. As a family-owned enterprise, bioMérieux upholds a commitment to by prioritizing long-term and environmental responsibility, which guides its investments in eco-friendly practices and enduring contributions to .

History

Origins and Early Development

The origins of bioMérieux trace back to 1897, when Marcel Mérieux, a student of , established the Institut Mérieux in , , to focus on and production for combating infectious diseases. This institution built on Pasteur's microbiological legacy by developing the first anti-tetanus and advancing vaccinology, initially targeting both human and veterinary applications. The Institut Mérieux laid the groundwork for biological diagnostics through its emphasis on research and production of sera for disease prevention. In 1963, the company that would become bioMérieux was founded as BD Mérieux, a between the Institut Mérieux and Becton Dickinson, aimed at producing diagnostic for testing. Alain Mérieux, grandson of the founder, initiated this partnership to expand into clinical diagnostics, with ownership split nearly evenly between the two entities to leverage combined expertise in and . The venture marked a shift from production toward diagnostic tools, concentrating on identifying pathogens in clinical and veterinary settings to support rapid disease detection. By 1974, Alain Mérieux acquired majority control from Becton Dickinson, renaming the company bioMérieux and redirecting it fully toward diagnostics (IVD). This transition solidified the firm's independence and strategic emphasis on innovative diagnostic solutions for infectious diseases. Following the acquisition of API Systems in 1986, bioMérieux integrated pioneering systems such as the API strips (launched in 1970) for biochemical of , which reduced testing time from days to hours, and the Galerie ™ system (introduced in 1979) for automated bacterial and testing. These developments enhanced pathogen accuracy and efficiency in both clinical laboratories and veterinary practices, establishing bioMérieux as a leader in microbiological diagnostics.

Expansion Through Acquisitions

Building on its early focus on reagents and manual testing methods developed in the 1960s, bioMérieux began a strategic expansion in the late 1980s through targeted acquisitions that diversified its microbiology portfolio. In 1986, the company acquired API Systems, a French firm specializing in bacterial identification strips, which enabled rapid and standardized microbial characterization in clinical labs. This move strengthened bioMérieux's position in manual diagnostic tools and laid the groundwork for automation. The following year, in 1988, bioMérieux acquired VITEK Systems from McDonnell Douglas in the United States, gaining expertise in automated microbial susceptibility testing and identification systems. VITEK's technology complemented API's offerings by introducing computerized workflows, reducing turnaround times for assessments and enhancing efficiency in hospital settings. Throughout the 1990s, bioMérieux pursued partnerships and selective acquisitions to venture into , aiming to integrate nucleic acid-based testing into its repertoire. A key development was the 2001 acquisition of Teknika's diagnostics division from Akzo Nobel, which provided assets in platforms and expanded capabilities in infectious disease detection. These efforts marked a shift toward advanced technologies beyond traditional culture methods. In 2004, bioMérieux completed its on , raising capital to fuel further growth and solidifying its status as a publicly traded entity. Collectively, these acquisitions transformed bioMérieux from a reagent-focused firm into a leader in automated and molecular solutions, significantly boosting its global in diagnostics.

Key Milestones Post-2000

In 2014, bioMérieux completed its acquisition of BioFire Diagnostics, a U.S.-based company specializing in , for $450 million plus approximately $35 million in net debt, enhancing its capabilities in PCR-based syndromic testing for infectious diseases. This move built on earlier expansions, such as the VITEK systems, by integrating BioFire's FilmArray platform into bioMérieux's portfolio for faster pathogen identification. Subsequent acquisitions included Specific Diagnostics in 2022 for rapid pathogen detection capabilities, LUMED in January 2024 to bolster software solutions against , and SpinChip Diagnostics in January 2025 to advance technologies. During the in 2020, bioMérieux rapidly developed and launched the R-GENE test, a for detecting the in respiratory samples, which received and became one of the first commercially available diagnostics. Concurrently, the company updated its BioFire FilmArray systems, including the BIOFIRE test and the Respiratory Panel 2.1, which detect alongside other respiratory pathogens in about 45 minutes, supporting widespread testing efforts globally. In 2021, bioMérieux introduced EPISEQ , a cloud-based genomic software solution designed for the surveillance and identification of variants from next-generation sequencing data, enabling labs to track mutations efficiently and report results with minimal hands-on time. This tool addressed the evolving challenges of variant detection during the pandemic's later stages. bioMérieux unveiled its GO·28 strategic plan in April 2024, a five-year initiative targeting 7% average annual organic revenue growth through 2028 by emphasizing , such as integration in diagnostics, and efforts including reduced environmental impact in operations. In 2025, the company earned two IMV ServiceTrak Clinical Laboratory Awards for excellence in systems, recognizing best system performance and best service based on surveys. Building on these developments, bioMérieux expanded into -driven diagnostics through a 2025 partnership with Mila, Quebec's institute, to develop models for genomic analysis and antibiotic resistance detection, aiming to improve diagnostic accuracy and speed. Additionally, the company advanced antimicrobial resistance initiatives, launching the Centers of Excellence program in 2021 to promote rapid diagnostics and stewardship practices in over 100 global sites, and co-leading the European Value Dx project to quantify diagnostics' role in combating .

Products and Technologies

Clinical Diagnostic Solutions

bioMérieux's clinical diagnostic solutions focus on diagnostics for human health, leveraging , immunodiagnostics, and technologies to support rapid and accurate testing in hospitals and laboratories. These offerings include automated systems, , and software designed to identify pathogens, monitor disease progression, and guide therapeutic decisions, thereby improving patient outcomes through timely results. In , bioMérieux provides the BIOFIRE FILMARRAY system, a multiplex platform that enables syndromic testing for multiple infectious agents simultaneously from a single sample, delivering results in about one hour. This technology, enhanced by the 2014 acquisition of BioFire Diagnostics, supports panels for respiratory, gastrointestinal, and , facilitating early intervention in critical care settings. The company also offers the BIOFIRE SPOTFIRE system, a point-of-care platform for rapid syndromic testing of respiratory and panels, providing results in about 15 minutes to aid near-patient decision-making. For immunodiagnostics, the VIDAS family of automated systems, including VIDAS 3 and VIDAS KUBE, uses enzyme-linked fluorescent assay (ELFA) technology for on-demand testing of high-value biomarkers. These systems offer flexibility for low- to medium-volume labs, processing up to 36 tests per hour with assays for infectious diseases, , and . In , the VITEK 2 system automates microbial identification (ID) and antibiotic susceptibility testing (AST), using advanced cards for identification of a comprehensive range of and species and provide minimum inhibitory concentrations (MICs) within hours. Recent innovations like VITEK COMPACT PRO, cleared by the FDA in 2025, enhance detection of , aiding in the fight against multidrug-resistant infections. These technologies apply to key clinical areas, including infectious disease , where multiplex and tools identify , viruses, and fungi to support . For cancer screening and monitoring, VIDAS immunoassays detect tumor markers such as () and cancer antigen 125 (CA 125), providing high medical value results for early detection and treatment tracking. In cardiovascular monitoring, and T assays on VIDAS platforms enable rapid assessment of acute risk, with high-sensitivity biomarkers aiding in the of heart attacks and chronic management. Supporting these diagnostics, bioMérieux offers VILINK software for laboratory connectivity, which provides remote monitoring, troubleshooting, and data security to ensure instrument uptime and seamless integration with lab information systems. Reagent kits, compatible with automated platforms like VITEK and VIDAS, enable efficient workflow automation, reducing manual steps and turnaround times. Innovations in PCR-based multiplex testing, such as panels run on the BIOFIRE FILMARRAY system, represent a shift toward comprehensive syndromic approaches, testing for up to 43 targets including genes in applications like , which has become standard in hospital emergency departments for faster pathogen detection and reduced empirical therapy. These advancements prioritize speed and accuracy, with systems validated for use in diverse clinical environments to enhance diagnostic precision without compromising reliability.

Industrial Microbiology Solutions

bioMérieux offers a range of industrial microbiology solutions designed to detect and identify microbial contaminants in non-clinical sectors, ensuring product safety and quality across various industries. These solutions encompass culture-based, automated, and molecular technologies tailored for rapid and reliable testing. In food safety applications, bioMérieux's tools focus on pathogen detection in agri-food products, such as dairy, meat, poultry, seafood, and produce, using molecular and culture-based methods to identify contaminants like bacteria and enable early product release. For pharmaceutical quality control, the company provides sterility testing solutions, including systems for microbial detection in sterile environments, which help maintain compliance with rigorous standards. Cosmetics testing benefits from similar quality control measures to prevent microbial spoilage, while environmental monitoring solutions address water and surface testing to mitigate contamination risks in production settings. Key products include ready-to-use culture media for traditional microbial growth and enumeration, automated systems like the PREVI instrument for efficient plate reading and counting, and molecular kits such as the BIOFIRE for contaminant through PCR-based detection. Additional offerings encompass the BACT/ for real-time microbial detection in sterility testing and the SCANRDI for automated microbial detection, alongside VITEK for and antibiotic susceptibility testing adapted for use. These products draw on shared technological platforms from bioMérieux's clinical diagnostics to enhance precision in industrial contexts. bioMérieux also provides services for method validation and , supporting adherence to standards such as FDA guidelines and EU pharmaceutical regulations through expertise-backed protocols and documentation tools. These services ensure that testing processes meet legal requirements for product safety and . The impact of these solutions lies in their ability to prevent microbial outbreaks by enabling swift detection and response, thereby safeguarding product integrity and consumer health in , pharmaceutical, , and environmental applications. For instance, testing reduces contamination risks in ready-to-eat foods and sterile drugs, contributing to safer processes and worldwide.

Operations and Global Reach

Manufacturing and R&D Facilities

bioMérieux operates 15 bio-industrial production sites worldwide, enabling the scalable manufacture of diagnostic reagents, instruments, and consumables to meet global demand. The company's primary hub is located in Marcy-l'Étoile, , near its , where teams produce reagents such as those for the VIDAS system. Additional French sites include La Balme-les-Grottes, specializing in reagents, and facilities in Saint-Vulbas and Verniolle for broader production needs. In the United States, key occurs at the BioFire Diagnostics campus in , , which serves as a center for molecular diagnostic instruments and panels, alongside sites in , for blood culture products like BacT/Alert, and in St. Louis, Missouri, and , for reagent and instrument assembly. For the region, bioMérieux maintains a and R&D site in to support regional supply chains. These facilities emphasize efficient, high-volume production to ensure timely global distribution. All production processes adhere to stringent quality standards, including certification for the design, manufacture, and distribution of diagnostic devices, ensuring compliance across sites for reagents and instruments. This certification supports bioMérieux's focus on reliability and in supply chains, with operations optimized for scalability to handle increased demand during events. The company invests approximately 12% of its annual revenue in , totaling €491.5 million in 2024, to drive in its facilities. R&D efforts are distributed across 16 global centers, with 900 dedicated personnel advancing core technologies in growth-based , , and immunoassays; notable sites include the molecular biology hub at BioFire in and the microbiology-focused center at La Balme-les-Grottes in . In 2024, bioMérieux inaugurated three new specialized R&D centers, including the Molecular and Genomic Center in , , to enhance in infectious disease diagnostics. Recent initiatives incorporate , such as a with Mila to enhance diagnostic algorithms for infectious diseases. Under its GO•28 strategic plan launched in 2024, bioMérieux prioritizes eco-friendly manufacturing initiatives as part of a broader commitment to sustainable growth, including efforts to reduce environmental impact through optimized resource use and waste minimization in production processes. This plan integrates responsible practices across operations, aligning with the company's CSR pillars and UN Global Compact principles to lower carbon footprints at sites like Marcy-l'Étoile and . For instance, initiatives focus on and energy-efficient production to support long-term environmental goals without compromising output quality.

International Presence and Markets

bioMérieux maintains a robust global footprint, operating subsidiaries in 45 countries and distributing its diagnostic solutions to more than 160 nations worldwide. This extensive network enables the company to address diverse healthcare needs across clinical and industrial sectors, supported by a combination of direct operations and distributor partnerships. The company's key markets reflect its international diversification, with accounting for approximately 45% of total sales in 2024, driven by strong demand in and industrial applications. , Middle East, and (EMEA), serving as the home base, contributed 32% of sales, benefiting from established infrastructure in and regulatory familiarity. The region represented 16% of sales, showing potential for expansion in markets like , though tempered by varying regional dynamics. added 7%, with notable growth in select countries. To navigate global trade complexities, bioMérieux employs strategies including local across 15 sites worldwide, which helps mitigate tariffs and optimize supply chains for regional compliance. In emerging markets, the company pursues partnerships, such as collaborations with governments and organizations in to enhance diagnostic access, exemplified by a 2024 multisectoral initiative in with the Ministry of Health and . Products are adapted to meet specific regional regulatory requirements, ensuring without extensive redesign. In 2025, bioMérieux faced challenges in the market, characterized by a continuous mid-teens percentage decline in sales due to competitive pressures and economic factors, prompting adjustments to its full-year growth guidance from at least 7% to between 5.5% and 6.5% at constant exchange rates. Despite this, the company reported overall organic sales growth of 3% in the third quarter, excluding and respiratory panels, underscoring resilience in other regions.

Corporate Governance

Executive Leadership

Pierre Boulud has served as of bioMérieux since July 1, 2023. With a background in consulting at and senior roles at pharmaceutical company over 14 years, Boulud joined bioMérieux in 2016 as a member of the Executive Committee and later as of Clinical Operations for three years. In his current role, he oversees the GO·28 strategic plan, a five-year initiative launched in 2024 to drive profitable growth through innovation in diagnostics, operational streamlining, and expanded solutions in clinical and industrial sectors. The Executive Committee supports Boulud in executing company strategy, comprising leaders with specialized expertise in , , and operations. Guillaume Bouhours has been since March 2018, directing financial strategy, purchasing, and information systems to ensure fiscal discipline and efficiency. Scientific innovation falls under Dr. Charles K. Cooper, Executive Vice President and since January 2024, who previously held senior positions in medical affairs at bioMérieux and brings over 25 years of experience in diagnostics and regulatory science. Céline Roger-Dalbert serves as Executive Vice President of Research & Development since March 2024, leading advancements in molecular and genomic technologies with a focus on biotech R&D. The clinical diagnostics division is led by Jennifer Zinn, Executive Vice President of Clinical Operations since August 2023, emphasizing global deployment of diagnostic solutions, while Yasha Mitrotti, Executive Vice President of Industrial Applications, heads offerings for and environmental testing, drawing on his extensive background in industrial biotech. These executives' tenures and specialized knowledge in diagnostics and life sciences foster continuity and drive bioMérieux's dual focus on healthcare and industrial applications. bioMérieux's , consisting of nine members, is chaired by Alexandre Mérieux, a descendant of the founding Mérieux family and executive from Institut Mérieux, the majority shareholder, promoting long-term family continuity in . Elected in 2004, Mérieux assumed the role of Chairman in June 2023, with his current term expiring in 2026. The board includes family representatives alongside independent directors like Marie-Paule Kieny (a virologist and former WHO advisor, term expires 2025) and Fanny Letier (technology executive, term expires 2025), who enhance oversight through specialized committees on , , , and CSR. Alain Mérieux, the company's Founding President and family patriarch, maintains an advisory role with a term expiring in 2025. This composition blends the Mérieux family's biotech heritage—rooted in the institute's legacy since 1897—with independent expertise in science, finance, and to align with sustainable and ethical practices.

Ownership and Shareholders

bioMérieux maintains a concentrated ownership structure dominated by family and institutional interests, with the Institut Mérieux, through its subsidiary Compagnie Mérieux SAS, holding a stake of 58.9% as of , a position that has remained stable since 2021. This underscores the company's roots in the Mérieux legacy, emphasizing continuity in strategic decision-making. Among other significant shareholders, the Dassault Family, via (GIMD), owns approximately 3%, while holds about 2%. Institutional investors also play a notable role, with , Inc. controlling 1.6% and , Inc. 1.3% of the shares. These holdings reflect a mix of long-term family and professional investment partnerships that support bioMérieux's operations in diagnostics and . Employee participation in ownership is facilitated through dedicated plans, with the bioMérieux Employee Stock Ownership Plan accounting for 0.79% of shares. In 2025, the MyShare global employee share ownership initiative further strengthened this alignment, enabling around 6,200 employees to subscribe and acquire approximately 200,000 shares, complete with employer matching contributions. The resulting of roughly 35% allows for while the family-led control fosters a focus on sustainable, long-term growth rather than short-term gains. This structure also ties into executive leadership, where family connections influence governance priorities.

Financial Performance

Revenue Growth and Key Metrics

bioMérieux's revenue has shown steady over the past several years, driven initially by heightened demand for diagnostic solutions during the and subsequently by expansions in and infectious disease testing. In 2020, the company reported consolidated sales of €3.118 billion, marking a 19.7% like-for-like increase from the previous year, largely attributable to volumes. Sales continued to rise in 2021 to approximately €3.376 billion, supported by sustained pandemic-related demand, before stabilizing in 2022 at around €3.587 billion with a 5.9% in the fourth quarter amid a post-peak . By 2023, revenue reached €3.675 billion, reflecting a 2.4% organic increase, and climbed to €3.980 billion in 2024, achieving 10.3% like-for-like exceeding initial guidance. In 2025, bioMérieux maintained its growth trajectory despite global economic challenges, particularly in key markets like . First-half sales totaled €2.044 billion, representing a 9.4% organic increase from €1.902 billion in the prior-year period. For the first nine months, consolidated sales amounted to €2.992 billion, with 7.3% organic growth aligning with updated annual expectations. The company adjusted its full-year 2025 guidance in November to project organic sales growth of 5.5% to 6.5% at constant exchange rates, down from the earlier range of 6% to 7.5%, primarily due to softer performance in respiratory panels and regional headwinds. This guidance factors in minimal currency impacts and scope effects from acquisitions, emphasizing organic contributions. Revenue is predominantly segmented between clinical and industrial applications, with clinical diagnostics accounting for approximately 85% of total sales in 2024 at €3.374 billion, while contributed the remaining 15% with solid double-digit growth in pharmaceutical . In the first half of 2025, clinical sales drove the majority of the 9.4% organic uplift through innovations in , whereas industrial applications grew 10% organically, bolstered by mid-teens expansion in pharma segments. Overall, has outpaced reported figures in recent years, with currency fluctuations and minor acquisition contributions adding 1-2% in 2024 and early 2025. Key growth drivers evolved from COVID-19 testing, which propelled 2020-2022 revenues, to sustained demand for infectious diagnostics thereafter, including BIOFIRE® panels and ® point-of-care solutions. In 2025, double-digit organic increases in non-respiratory BIOFIRE® panels (+10%) and ® (+143% in H1) offset seasonal declines in respiratory testing, underscoring a shift toward diversified infectious portfolios. This strategic focus under the GO•28 plan has supported resilient expansion amid post-pandemic market dynamics.

Profitability and Stock Listing

In the first half of 2025, bioMérieux reported contributive (CEBIT) of €372 million, reflecting a 24% increase on a like-for-like basis compared to the prior year period. attributable to the group stood at €161 million, marking a 25.3% decline year-over-year, primarily due to a €146 million charge on its Reveal technology for susceptibility testing. generation strengthened significantly to €170 million, more than tripling from the first half of 2024, driven by improved EBITDA and management. The company's operating margin reached approximately 18% in 2025, with the H1 margin specifically at 18.2% of sales, an improvement of 210 basis points from the previous year. This enhancement in profitability was bolstered by the ongoing execution of the GO·28 strategic plan, which focuses on process simplification, efficiency gains, and cost optimizations across operations. bioMérieux has been publicly listed since its in June 2004 on , where it trades under the ticker BIM.PA. As of November 2025, the company's trailing twelve-month revenue was €4.12 billion ($4.45 billion USD), with an enterprise value of around €12.83 billion ($13.85 billion USD), underscoring its position as a key player in the diagnostics sector. The firm has maintained consistent payouts to shareholders, reflecting stable financial health. At the annual general meeting on May 15, 2025, shareholders approved a of €0.90 per share for the 2024 fiscal year, an increase from the prior year's €0.85.

References

  1. [1]
    Who we are | Pioneering Diagnostics - bioMerieux
    A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics.Our legacy · bioMérieux at a glance · Our Company Purpose · Company News
  2. [2]
    Our legacy | Pioneering Diagnostics - bioMerieux
    bioMérieux was created in 1963, but our roots go all the way back to the 19th century, with Marcel Mérieux, a student of Louis Pasteur.
  3. [3]
    Employees | Pioneering Diagnostics - bioMerieux
    Today, we are 14,600 team members, each of us with a unique story. That is why we strive to build an inclusive workplace that fosters well-being, inclusion and ...
  4. [4]
    bioMérieux at a glance | Pioneering Diagnostics - bioMerieux
    A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ...
  5. [5]
    Our Offer | Pioneering Diagnostics - bioMerieux
    We develop equipment, tests and software that deliver rapid, high-impact, actionable results in immunoassays, microbiology and molecular biology.BioFire FilmArray · In Hospital / In Lab · BIOFIRE ® Respiratory 2.1 Panel · Vilink
  6. [6]
    Research and Development | Pioneering Diagnostics - bioMerieux
    bioMérieux's R&D draws on more than a century of expertise in infectious disease management and a unique mastery of the three core technologies.
  7. [7]
    bioMérieux Worldwide | Pioneering Diagnostics - bioMerieux
    bioMérieux has experienced more than 60 years of international development. It is today present in 45 countries and serves more than 160 countries.
  8. [8]
    Third-Quarter 2025 Business Review
    ### Summary of Third-Quarter 2025 Business Review
  9. [9]
    Our legacy | Pioneering Diagnostics - bioMerieux
    bioMérieux was created in 1963, but our roots go all the way back to the 19th century, with Marcel Mérieux, a student of Louis Pasteur.
  10. [10]
    A Pasteurian tradition - INSTITUT MERIEUX
    The Mérieux family's commitment to the field of biology began in 1897, when Marcel Mérieux, a student of Louis Pasteur and Émile Roux, founded Institut Mérieux.
  11. [11]
    BIOMERIEUX | FR0013280286 | Euronext exchange Live quotes
    Stock BIOMERIEUX Common Stock FR0013280286 XPAR Euronext Paris Euronext Tech Leaders Live Euronext quotes, realtime prices, charts and regulated news.
  12. [12]
    Legal Notice | Pioneering Diagnostics - bioMerieux
    ... Lyon trade and companies register under number 673 620 399, whose registered office is located in MARCY L'ETOILE (69280) and whose publication director is Mr.
  13. [13]
    Institut Mérieux
    Institut Mérieux is an independent, family-owned French group established in 1897 following in the footsteps of Louis Pasteur, serving medicine and Public ...Missing: Marcel | Show results with:Marcel
  14. [14]
    Our Company Purpose | Pioneering Diagnostics - bioMerieux
    We pioneer, develop and produce high quality in vitro diagnostics to improve public health worldwide. We sustain a robust business model that allows us to ...
  15. [15]
    Clinical Laboratories | Pioneering Diagnostics - bioMerieux
    bioMérieux contributes to the diagnosis of infectious diseases, cardiovascular diseases and cancer through three technologies: microbiology, immunodiagnostics, ...
  16. [16]
    Industrial Microbiology Applications | Pioneering Diagnostics
    Our mission is to provide the food and pharmaceutical industries with innovative, precise technologies that help you manufacture safe products.
  17. [17]
    Non-Sterile Pharma & Personal Care - bioMerieux
    To ensure greater safety and efficiency in non-sterile pharmaceutical and personal care settings, bioMérieux offers a range of rapid and reliable microbiology ...
  18. [18]
    [PDF] bioMérieux – 2023 Financial Results - bioMerieux
    Mar 14, 2024 · Sales in Europe – Middle East – Africa region (32% of the total annual sales) came to €327 million for the fourth quarter, up 7% compared with ...
  19. [19]
    Our Responsibility | Pioneering Diagnostics - bioMerieux
    As a pioneer in the field of in vitro diagnostics for 60 years, bioMérieux is committed to fighting against infectious diseases worldwide.
  20. [20]
    Notre histoire | Pioneering Diagnostics - bioMerieux
    bioMérieux a été créée en 1963 mais nos racines plongent jusqu'à la fin du 19ème siècle, avec Marcel Mérieux, élève de Louis Pasteur. Découvrez les étapes clés ...
  21. [21]
    The history of bioMérieux - bioMerieux Industry
    In 1897 Marcel Mérieux founded the Institut Mérieux in Lyon where he developed the first anti-tetanus serum. Building on the institute's work in vaccinology and ...Missing: milestones | Show results with:milestones
  22. [22]
    Les temps forts - INSTITUT MERIEUX
    bioMérieux. 1974. Alain Mérieux prend le contrôle de BD Mérieux qui devient bioMérieux. Article Mérieuscope 1985. Institut Pasteur Production.
  23. [23]
    [PDF] bioMérieux-2023-Annual-Report.pdf.coredownload.pdf - bioMerieux
    Jan 2, 2024 · of sales in 2023,. +131% in ten years time. OVER 90%. OF SALES OUTSIDE. OF FRANCE. 84%. OF SALES. 16%. OF SALES. 14,600. TEAM MEMBERS IN 2023, ...
  24. [24]
    Highlights - INSTITUT MERIEUX
    BD Mérieux. 1963. Alain Mérieux creates BD Mérieux, an in vitro diagnostics company jointly owned by Institut Mérieux and Becton Dickinson. Dr. Charles ...Missing: venture | Show results with:venture
  25. [25]
    [PDF] REFERENCE DOCUMENT - bioMerieux
    When it was formed in 1963, B-D Mérieux (as the Company was formerly known) was owned by Institut Mérieux (49.95%) and Becton-Dickinson France (49.96%) with.
  26. [26]
    Api 20e test, by bioMérieux - Product details - Pubcompare
    Its development in the 1970s dramatically reduced identification time from days to hours, enabling faster pathogen detection and contributing significantly ...
  27. [27]
    Automated Microbial Identification Systems | Taylor & Francis Group
    In the early 1970s, API (bioMerieux Vitek) introduced lyophilized substrates in microcupules that allowed many clinical isolates to be identi fied in 24-48 hr.Missing: innovations | Show results with:innovations
  28. [28]
    [PDF] bioMérieux 2 013 - AnnualReports.com
    Dec 31, 2013 · Strategy Committee. This committee is comprised of Alain Mérieux, Jean-Luc Belingard and Alexandre Mérieux. Management Committee. The Management ...
  29. [29]
    bioMérieux S.A. | Encyclopedia.com
    bioMérieux S.A. is one of the world's largest specialists in the development of in vitro diagnostic methods, systems, and applications.Missing: milestones | Show results with:milestones<|control11|><|separator|>
  30. [30]
    bioMerieux Acquires Organon Teknika | Mergr M&A Deal Summary
    Jan 1, 2001 · On January 1, 2001, bioMerieux acquired medical products company Organon Teknika from Akzo Nobel. Acquisition Highlights.
  31. [31]
    https://www.encyclopedia.com/books/politics-and-business-magazines/biomerieux-sa
  32. [32]
    BioMerieux buys diagnostics rival BioFire for $450 mln - Reuters
    Sep 4, 2013 · French biotech firm BioMerieux will buy privately-owned US rival BioFire Diagnostics for $450 million, in a deal aimed at consolidating its position as a major ...<|control11|><|separator|>
  33. [33]
    BioMérieux closes BioFire Diagnostics deal for $450M plus debt
    Jan 17, 2014 · Under the agreement, bioMérieux will pay $450 million and will also assume BioFire's net financial debt, which is estimated at $35 million.
  34. [34]
    First of 3 diagnostic tests for SARS-CoV-2 coronavirus available ...
    Mar 11, 2020 · bioMérieux has finalized the development of the SARS-COV-2 R-GENE® test. This real-time PCR test is clinically validated on one type of respiratory specimen.
  35. [35]
    [PDF] bioMérieux receives Emergency Use Authorization for BIOFIRE ...
    Mar 24, 2020 · The BIOFIRE® COVID-19 test detects SARS-CoV-2 in approximately 45 minutes from a nasopharyngeal swab in transport media. This test runs on the ...
  36. [36]
    [PDF] BIOFIRE® Respiratory Panel 2.1 (RP2.1) with SARS-CoV-2 obtains ...
    May 4, 2020 · A BIOFIRE® FILMARRAY® test requires only two minutes of hands-on time and has a total run time of about 45 to 75 minutes, depending on the ...<|control11|><|separator|>
  37. [37]
    [PDF] bioMérieux launches EPISEQ® SARS-COV-2, a cloud-based ...
    Marcy l'Étoile, France – June 24th, 2021 – bioMérieux, a world leader in the field of in vitro diagnostics, has launched EPISEQ® SARS-COV-2, a genomic software.
  38. [38]
    bioMérieux presents its new 5-year strategic plan and its targets for ...
    Apr 9, 2024 · With the GO•28 plan, we are presenting today an ambitious medium term strategy for profitable and sustainable growth to better serve our purpose.Missing: transformation | Show results with:transformation
  39. [39]
    bioMérieux Recognized with 2025 IMV ServiceTrak™ Clinical ...
    Aug 5, 2025 · bioMérieux received two 2025 IMV ServiceTrak™ Clinical Laboratory Awards for excellence in Immunoassay, highlighting bioMérieux's continued ...
  40. [40]
    bioMérieux partners with Mila to harness artificial intelligence for ...
    This partnership aims to develop innovative solutions to improve the accuracy and efficiency of in vitro diagnostic tools and detection of antibiotic resistance ...Missing: expansion post- 2000
  41. [41]
    Antimicrobial Stewardship Solutions, Fight Antimicrobial Resistance
    In 2021, bioMérieux established the Antimicrobial Stewardship Centers of Excellence program to bring attention to the threat of antimicrobial resistance and ...Antimicrobial Resistance · Biomérieux - Your Partner... · The Fleming Fund
  42. [42]
    BIOMÉRIEUX LEADS EUROPEAN EFFORT TO QUANTIFY ...
    Through its co-leadership on the Value Dx Project, bioMérieux is accelerating pan-European efforts to quantify the medical, economic, and public health ...
  43. [43]
    bioMérieux (Clinical Diagnostics) details - Rapid Microbiology
    bioMérieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination to improve patient health ...
  44. [44]
    BIOFIRE® FILMARRAY® | Pioneering Diagnostics - bioMerieux
    The FILMARRAY is an FDA-cleared multiplex PCR system that integrates sample preparation, amplification, detection and analysis.Missing: VIDAS VITEK
  45. [45]
    BioFire is Now bioMérieux | One Company. Endless Possibilities
    bioMérieux was founded in 1963 and has grown into a global leader in clinical diagnostics and industrial microbiology with a presence in 44 countries and a ...Missing: milestones | Show results with:milestones
  46. [46]
    VIDAS® Immunoassay Diagnostics, Equipment & Biomarkers
    VIDAS® systems and extensive menu of high-quality assays provide best-in-class, on-demand immunoassay testing for emergency and critical care, immunochemistry, ...
  47. [47]
    VIDAS® 3 | Pioneering Diagnostics - bioMerieux
    VIDAS 3 is a fully automated benchtop immunoassay system based on the proven enzyme-linked fluorescent assay (ELFA) technology, for high-quality on-demand test ...
  48. [48]
    VITEK® 2 | Pioneering Diagnostics - bioMerieux
    The VITEK 2 system has everything healthcare laboratories need for fast, accurate microbial identification, and antibiotic susceptibility testing.
  49. [49]
    bioMérieux receives FDA 510(k) Clearance for its VITEK ...
    Mar 18, 2025 · This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose ...
  50. [50]
    Infectious Diseases | Pioneering Diagnostics - bioMerieux
    The history of bioMérieux is directly linked to the fight against infectious diseases. bioMérieux provides tests for the early detection of infectious diseases ...
  51. [51]
    VILINK® | Pioneering Diagnostics - bioMerieux
    VILINK provides a direct connection between bioMérieux's technical support representative and your systems. It features full traceability and data security via ...
  52. [52]
    Connectivity and Data IT | Pioneering Diagnostics - bioMerieux
    VILINK® diagnoses, solves software and instrument issues, and supports your systems to enable laboratory productivity and efficiency improvements. View ...
  53. [53]
    BIOFIRE® FILMARRAY® TORCH - bioMerieux
    BIOFIRE FILMARRAY TORCH is a multiplex PCR system that enables simultaneous testing for bacteria, viruses, yeast, parasites, and/or antimicrobial resistant ...
  54. [54]
    Molecular Diagnostics Testing Solutions - bioMerieux
    Our offer includes flexible molecular systems and integrated multiplex PCR systems with a broad menu of high-quality in vitro diagnostics, plus expert support.
  55. [55]
    Food Safety and Quality | Pioneering Diagnostics - bioMerieux
    Our products and solutions provide fast, accurate, and consistent results so that you can manufacture safe, high-quality ready-to-eat foods.
  56. [56]
    bioMérieux (Pharma Quality Control) - Rapid Microbiology
    bioMérieux offers solutions for environmental, sterility, endotoxin, mycoplasma, and microbial testing, plus microbiological quality control strains and ...<|control11|><|separator|>
  57. [57]
    Pioneering diagnostics to improve public health | bioMérieux ...
    bioMérieux Industry provides microbiological testing solutions. Our mission is to provide the food and pharmaceutical industries with precise technologies ...Missing: mission statement
  58. [58]
    [PDF] 2022 ANNUAL REPORT | bioMerieux
    Jun 2, 2023 · To date, 13 centers have been established worldwide. The final list of partners shows a wide diversity in terms of type of structure. (private/ ...<|separator|>
  59. [59]
    bioMérieux Marcy l'Étoile (France) - YouTube
    Jul 28, 2021 · Save. Report. Comments. Add a comment... 4:24. Go to channel · Oval Office Press Conference Cold Open - SNL. Saturday Night Live New 2.1M views.Missing: Lyon | Show results with:Lyon
  60. [60]
    the bioMérieux bioindustrial and R&D site of La Balme is diversifying
    Sep 2, 2024 · Already specialized in the manufacturing of reagents for microbiology solutions, the bioMérieux site in La Balme-les-Grottes is diversifying its ...
  61. [61]
    Around the world - YouTube
    bioMérieux Saint Vulbas (France) · bioMérieux India (Manufacturing + R&D Site) · bioMérieux Spain · bioMérieux Verniolle (France) · bioMérieux Lombard, IL (USA).Missing: production facilities worldwide
  62. [62]
    About bioMérieux Connection
    bioMérieux, Inc. represents the group throughout the Americas region with headquarters based in Durham, NC, manufacturing sites in St. Louis and Lombard ...Missing: facilities | Show results with:facilities
  63. [63]
    BioFire opens new Utah facility with multinational partner
    May 17, 2017 · Mérieux said the new facility could accommodate the growth for BioFire's manufacturing for the next five to 10 years. He also said that the new ...<|separator|>
  64. [64]
    bioMérieux Breaks Ground on New Production Line at Durham Facility
    “This new production line for our BacT/Alert blood culture bottles represents a significant investment for our Durham manufacturing facility,” said Stefan ...
  65. [65]
    Quality Certificates | Pioneering Diagnostics - bioMerieux
    Find here our Products Quality Certificates which concern the legal manufacturer and click on the link to consult the document. ETEST®. ISO 9001 · ISO 13485.
  66. [66]
    [PDF] bioMérieux, Inc. - bioMerieux
    For the following activities. Design, manufacture and distribution of instruments and reagents for in vitro diagnostics. This certificate is valid from 03 June ...
  67. [67]
    bioMerieux SA Analysis & Company Information - GlobalData
    In FY2024, bioMerieux spent EUR491.5 million on its R&D activities, which as a percentage of revenue, stood at 12.3% and grew 6.8% YoY. As of December 31 ...
  68. [68]
    bioMérieux inaugurates a new multidisciplinary R&D center for ...
    Oct 10, 2014 · The R&D Center at La Balme-Les-Grottes is specialized in the development of new diagnostic solutions in microbiology: high medical value tests ...
  69. [69]
    Our Responsibility
    ### Summary of Sustainability Initiatives in Manufacturing under GO 28 Plan
  70. [70]
    [PDF] bioMérieux – Third-Quarter 2025 Business Review - bioMerieux
    A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than. 160 countries with ...Missing: international subsidiaries
  71. [71]
    [PDF] CHIEF EXECUTIVE OFFICER CHIEF FINANCIAL OFFICER
    Mar 7, 2025 · FY 2024 sales by geography. EMEA. €1,269m. 32% of sales. +7%*. ASPAC. €656m. 16% of sales. +5%*. LATAM. €262m. 7% of sales. +33%*. NORAM. €1,793 ...
  72. [72]
    Industrial Operations & Supply Chain - bioMerieux
    We produce high quality products leveraging our footprint of 15 manufacturing sites around the world. We capitalize on our bio-industrial expertise.Missing: facilities | Show results with:facilities
  73. [73]
    Malawi Ministry of Health, bioMérieux, and Pfizer Form Country's ...
    May 23, 2024 · The Malawi Ministry of Health, bioMérieux, and Pfizer today announced a collaboration to advance Malawi's first multisectoral initiative.
  74. [74]
    Our Innovation strategy | Pioneering Diagnostics - bioMerieux
    Our R&D teams combine their knowledge of medicine with emerging techniques and new technologies to combat infectious diseases worldwide.Missing: manufacturing markets
  75. [75]
    [PDF] Alexandre Mérieux becomes Executive Chairman. Pierre Boulud is ...
    Jun 14, 2023 · Biography of Pierre Boulud: After a career at Boston Consulting Group and Ipsen, Pierre Boulud joined bioMérieux in November 2016, as member ...
  76. [76]
    Executive Committee | Pioneering Diagnostics - bioMerieux
    Pierre Boulud, Chief Executive Officer, Guillaume Bouhours, Chief Financial Officer, Executive Vice President, Purchasing and Information Systems.
  77. [77]
    bioMérieux announces nomination of two new Executive Committee ...
    Jan 16, 2024 · Dr. Charles K. Cooper succeeds Dr. Mark Miller, as Executive Vice President, Chief Medical Officer, effective January 2nd, 2024.
  78. [78]
    bioMérieux: Governance, Directors and Executives & Committees
    Executive Committee: bioMérieux ; Pierre Boulud. 53 year. Chief Executive Officer, 2023-06-30 ; Audrey Dauvet. General Counsel, 2022-12-31 ; Charles Cooper. Chief ...
  79. [79]
    Board of Directors & Committees - bioMerieux
    Expiration date of current term: 2025. Board Members. Alexandre Mérieux Executive Chairman of bioMérieux. First elected on: April 16, 2004; Expiration date of ...
  80. [80]
    Major shareholders: BioMerieux SA - MarketScreener
    Major shareholders: BioMerieux SA ; Dassault Family. 3.002 %. 3,553,520, 3.002 %, 490 M € ; Sofina SA (Private Equity). 1.928 %. 2,282,513, 1.928 %, 315 M €.
  81. [81]
    BIOMERIEUX | FR0013280286 | Company information
    BIOMERIEUX. Euronext Paris FR0013280286 - Stock. CAC 40 -0.18% SBF 120 -0.20% EUR / USD 0.20% EUR / GBP -0.02%. € 106.60. Last traded price. 07/11/2025 - 17 ...Missing: legal Société Anonyme BIM ISIN Next
  82. [82]
    https://www.biomerieux.com/content/dam/biomerieux-com/investor/regulated-informations/2023/releases/bioM%25C3%25A9rieux_PR_Governance_20230614.pdf
  83. [83]
    Who Owns Biomerieux? BIOX Shareholders - Investing.com
    Top Institutional Holders ; The Vanguard Group, Inc. 1.60%, 1,890,374, Sep 29, 2025, 201,514 ; BlackRock, Inc. 1.34%, 1,584,581, Mar 30, 2025, 168,916.Missing: structure | Show results with:structure
  84. [84]
    [PDF] bioMérieux – First-Half 2025 Results - bioMerieux
    Sep 4, 2025 · In 2024, revenues reached €4.0 billion, with over 93% of sales outside of France. bioMérieux provides diagnostic solutions (systems ...
  85. [85]
    bioMérieux: Shareholders Board Members Managers and Company ...
    bioMérieux Italia SpA engages in research and development activities in the clinical diagnostics and industrial microbiology sectors. The firm focuses on ...
  86. [86]
    bioMérieux – 2020 Financial Results - Nasdaq
    Feb 24, 2021 · €3,118 million in full-year 2020 sales, up 19.7 % like-for-like · Robust sales performance in the fourth quarter, with organic growth of 20.5 % ...
  87. [87]
    bioMérieux: Financial Data Forecasts Estimates and Expectations
    Projected Income Statement: bioMérieux ; Net sales · 3,118, 3,376 ; Change, -, 8.27% ; EBITDA · 823.5, 1,032 ; Change, -, 25.34% ...
  88. [88]
    2024 Financial Results | Pioneering Diagnostics - bioMérieux
    Mar 7, 2025 · Consolidated sales amounted to €3980 million in 2024, up 10.3% like-for-like from €3675 million in the prior year period.
  89. [89]
    First-Half 2025 Financial Results | Pioneering Diagnostics
    H1 2025 saw +9.4% organic sales growth to €2,044M, €372M CEBIT, €161M net income, and €170M free cash flow. Full year sales are expected to grow 6-7.5%.
  90. [90]
    [PDF] bioMérieux – 2024 Financial Results - bioMerieux
    Mar 7, 2025 · Clinical applications sales (85% of 2024 bioMérieux's total sales), rose by 10% in the fourth quarter to €947 million and reached €3,374 ...Missing: 2020 2021 2022
  91. [91]
    bioMérieux Posts Strong H1 2025 Results Despite Challenges
    Sep 7, 2025 · bioMérieux reported a 9.4% sales growth in the first half of 2025, driven by double-digit growth in its key drivers, including BIOFIRE ...
  92. [92]
    Assessing bioMérieux's H1 Performance and Guidance Outlook in a ...
    Sep 4, 2025 · - BioMérieux reported €2,044M H1 2025 sales (+9.4% organic growth), driven by SPOTFIRE® (+143%) and BIOFIRE® respiratory panels (+12%) surges.<|separator|>
  93. [93]
    BioMerieux : First-Half 2025 Financial Results | MarketScreener
    Sep 4, 2025 · +9.4% organic sales growth in H1 25, reaching €2,044 million, driven by a +10% organic sales increase across the four growth drivers of the GO• ...
  94. [94]
    [PDF] H1 2025 Results & 2025 outlook - bioMerieux
    * MyShare: worldwide employee share ownership plan. ** Per € million of ... All data as of June 2025, except for Philantropy & referenced antibiotics (Dec 24 data)
  95. [95]
    BIOMERIEUX (BIM.PA) Stock Price, Forecast & Analysis - Chartmill
    Rating 4.5/10 (3) The company went IPO on 2004-06-07. The firm designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of ...
  96. [96]
    bioMérieux (BIM.PA) - Revenue - Companies Market Cap
    In 2024 the company made a revenue of $4.14 Billion USD an increase over the revenue in the year 2023 that were of $4.06 Billion USD.
  97. [97]
    [PDF] May 15, 2025 - bioMerieux
    May 15, 2025 · This email must contain the following information: the name of the company concerned (bioMérieux), the date of the meeting (May 15, 2025), your ...